CEO confirms GLP-1 users driving preventive and corrective aesthetics demand—practices should prepare for sustained volume and case-mix shifts.
Galderma's CEO confirmed that the surge in GLP-1 weight-loss drug adoption is directly boosting the company's aesthetics sales by approximately 25%, a material contribution to the company's record H1 2026 performance. The driver is twofold: GLP-1 users seeking preventive injectables to mitigate "Ozempic face" (volume loss, skin laxity) and corrective procedures post-weight loss (skin tightening, filler for restored contour).
This is not speculative. Galderma's data shows measurable uptick in Dysport, Radiesse, and Sculptra volume among practices serving GLP-1-using patient cohorts. The effect is strongest in urban, higher-income markets where GLP-1 penetration is highest.
Galderma CEO: GLP-1 weight-loss drugs are driving 25% of aesthetics sales growth—preventive and corrective demand both rising.
For practices, the implication is clear: GLP-1 adoption is reshaping case mix and patient acquisition. Practices in markets with high GLP-1 penetration should expect sustained demand for preventive toxin, volumizing fillers, and biostimulators. Marketing messaging around "GLP-1 support" and skin quality maintenance is becoming table stakes. Expect this tailwind to persist as GLP-1 adoption continues to climb.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
